Drug:
Reaction: ASTHMA
20260101 - 20261231
No. 1201 - 1300
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1201 | 26742929 |
US |
56 | 2 |
Anxiety, Vomiting, Dyspnoea, Asthma, |
||||
DUPILUMAB, |
||||
| 1202 | 26743270 |
US |
70 | 2 |
Asthma, Dyspnoea exertional, Cough, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1203 | 26743296 |
US |
37 | 2 |
White blood cell count increased, Asthma, |
||||
DUPILUMAB, |
||||
| 1204 | 26743302 |
US |
37 | 2 |
Asthma, |
||||
DUPILUMAB, |
||||
| 1205 | 26743499 |
US |
55 | 1 |
Type 2 diabetes mellitus, Lipoprotein deficiency, Vitamin B complex deficiency, Vitamin D deficiency, Gout, Rhinitis allergic, Obstructive sleep apnoea syndrome, Atelectasis, Lung consolidation, Asthma, Affective disorder, Metabolic syndrome, Haemoglobin decreased, Mean cell haemoglobin decreased, Mean cell haemoglobin concentration decreased, Red cell distribution width increased, Platelet count increased, Neutrophil count increased, |
||||
EVOLOCUMAB, TEZEPELUMAB-EKKO, METHYLPREDNISOLONE, ALBUTEROL SULFATE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, BENZONATATE, CEFDINIR, ERGOCALCIFEROL, CITALOPRAM, CITALOPRAM HYDROBROMIDE, CLONAZEPAM, FAMOTIDINE, FERROUS SULFATE, FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE NASAL, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, LOSARTAN, PANTOPRAZOLE, TIOTROPIUM BROMIDE INHALATION SPRAY, |
||||
| 1206 | 26743586 |
US |
1 | |
Autism spectrum disorder, Asthma, |
||||
| 1207 | 26743668 |
US |
62 | 2 |
Asthma, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 1208 | 26743731 |
US |
58 | 2 |
Asthma, Rash, |
||||
DUPILUMAB, |
||||
| 1209 | 26743789 |
GB |
1 | |
Asthma, |
||||
USTEKINUMAB, |
||||
| 1210 | 26744162 |
US |
67 | 2 |
Asthma, |
||||
DUPILUMAB, |
||||
| 1211 | 26744166 |
US |
2 | |
Asthma, Drug ineffective, |
||||
MEPOLIZUMAB, |
||||
| 1212 | 26744192 |
US |
54 | 2 |
Asthma, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1213 | 26744596 |
US |
54 | 2 |
Asthma, Bipolar disorder, Constipation, Influenza, Nasopharyngitis, |
||||
DUPILUMAB, TIRZEPATIDE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, ARIPIPRAZOLE ORALLY DISINTEGRATING, ARIPIPRAZOLE, ARIPIPRAZOLE ORAL, ATENOLOL, BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, CYANOCOBALAMIN, FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE ORAL, FEXOFENADINE HCL, FUROSEMIDE, ISOSORBIDE MONONITRATE, LACTULOSE, MONTELUKAST SODIUM, MONTELUKAST, NORTRIPTYLINE HYDROCHLORIDE, |
||||
| 1214 | 26744704 |
US |
73 | 2 |
Asthma, Dyspnoea, Illness, Disturbance in attention, Product dose omission issue, Product cleaning inadequate, Device delivery system issue, |
||||
BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, |
||||
| 1215 | 26745036 |
US |
21 | 2 |
Asthma, Product dose omission issue, Eczema, Product dose omission in error, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 1216 | 26745427 |
US |
78 | 2 |
Asthma, |
||||
DUPILUMAB, |
||||
| 1217 | 26745437 |
CA |
53 | 2 |
Pneumonia, Cough, Asthma, Fatigue, |
||||
DUPILUMAB, DUPILUMAB, HYDROCORTISONE, ANTIPRURITIC (ANTI-ITCH), ANTI-ITCH CREAM, HYDROCORTISONE CREAM, HYDROCORTISONE 1%, HYDROCORTISONE CREAM 1%, HYDROCORTISONE CREAM 1/2%, ANTI-PRURITIC, HYDROCORTISONE CONTINUOUS SPRAY, HYDROCORTISONE LOTION, HYDROCORTISONE ACETATE, ANTI-ITCH, COOL RELIEF GEL WITH ALOE, HYDROCORTISONE SPRAY, DRS. HYDROCORTISONE, DESOXIMETASONE, PIMECROLIMUS, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 1218 | 26745456 |
US |
1 | |
Asthma, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 1219 | 26745755 |
KR |
36 | 2 |
Septic shock, Pyelonephritis acute, Oliguria, Blood pressure decreased, Ureterolithiasis, Breast cancer, Malignant neoplasm progression, Pyrexia, Nephrolithiasis, Flank pain, Dizziness, Acute kidney injury, Eosinophilia, Hyperglycaemia, Liver function test increased, Dyspnoea, Somnolence, Asthma, Cough, Headache, Rash, Diarrhoea, Nausea, Fatigue, |
||||
FULVESTRANT, |
||||
| 1220 | 26746079 |
US |
12 | 2 |
Dyspnoea, Illness, Injection site haemorrhage, Asthma, |
||||
DUPILUMAB, |
||||
| 1221 | 26746122 |
US |
60 | 2 |
Asthma, |
||||
DUPILUMAB, |
||||
| 1222 | 26746318 |
US |
85 | 1 |
Injection site haemorrhage, Asthma, Incorrect dose administered, Device mechanical issue, |
||||
DUPILUMAB, |
||||
| 1223 | 26746336 |
US |
25 | 2 |
Asthma, Bronchitis, |
||||
DUPILUMAB, |
||||
| 1224 | 26746352 |
US |
1 | |
Asthma, Injection site pain, |
||||
DUPILUMAB, |
||||
| 1225 | 26749875 |
71 | 1 | |
Asthma, Bronchitis, Wheezing, |
||||
SILDENAFIL CITRATE, SILDENAFIL, SILDENAFIL POWDER,, |
||||
| 1226 | 26749899 |
|||
Asthma, Therapy interrupted, |
||||
TEZEPELUMAB-EKKO, |
||||
| 1227 | 26736156 |
US |
2 | |
Asthma, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1228 | 26736186 |
KR |
||
Asthma, Acne, Dizziness, Muscle twitching, Facial paralysis, Arthralgia, Diplopia, Abdominal pain, Dyspnoea, Obliterative bronchiolitis, Oxygen saturation decreased, Pulmonary function test decreased, Asthenia, Interstitial lung disease, |
||||
UPADACITINIB, |
||||
| 1229 | 26736221 |
CA |
2 | |
Lower respiratory tract infection, Asthma, |
||||
CICLESONIDE, ALBUTEROL SULFATE, MOMETASONE FUROATE, |
||||
| 1230 | 26736320 |
US |
47 | 1 |
Asthma, Product use in unapproved indication, |
||||
DUPILUMAB, LORATADINE, LORATADINE TABLET, |
||||
| 1231 | 26736341 |
GB |
55 | 2 |
Lower respiratory tract infection, Asthma, |
||||
| 1232 | 26736433 |
US |
||
Liquid product physical issue, Asthma, |
||||
TEZEPELUMAB-EKKO, TEZEPELUMAB-EKKO, |
||||
| 1233 | 26736442 |
US |
2 | |
Asthma, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 1234 | 26737030 |
US |
2 | |
Asthma, Rhinitis allergic, Condition aggravated, |
||||
DENOSUMAB, |
||||
| 1235 | 26737090 |
CA |
2 | |
Pulmonary mass, Pleural effusion, Productive cough, Blood glucose decreased, Pulmonary congestion, Hernia, Asthma, Dyspnoea, Neuropathy peripheral, |
||||
LEFLUNOMIDE, ADALIMUMAB-FKJP, ADALIMUMAB-FKJP, |
||||
| 1236 | 26737128 |
US |
2 | |
Asthma, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 1237 | 26737153 |
US |
2 | |
Asthma, |
||||
OMALIZUMAB, |
||||
| 1238 | 26737653 |
US |
65 | 2 |
Asthma, |
||||
DUPILUMAB, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, AZELASTINE, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, |
||||
| 1239 | 26737706 |
US |
57 | 1 |
Upper respiratory tract infection, Asthma, |
||||
DUPILUMAB, |
||||
| 1240 | 26737709 |
US |
31 | 1 |
Asthma, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1241 | 26737711 |
US |
52 | 2 |
Asthma, |
||||
DUPILUMAB, |
||||
| 1242 | 26737748 |
US |
28 | 1 |
Asthma, Respiratory tract congestion, |
||||
DUPILUMAB, |
||||
| 1243 | 26737753 |
US |
61 | 2 |
Asthma, Product dose omission issue, Product use in unapproved indication, |
||||
DUPILUMAB, ALBUTEROL SULFATE, ALBUTEROL, FLUTICASONE PROPIONATE, GABAPENTIN, LISINOPRIL, MONTELUKAST, OXYCODONE, FLUTICASONE PROPIONATE AND SALMETEROL, |
||||
| 1244 | 26737764 |
US |
19 | 2 |
Illness, Asthma, |
||||
DUPILUMAB, |
||||
| 1245 | 26737783 |
CA |
84 | 1 |
Aspiration, Dyspnoea, Pneumonia pseudomonal, Infection, Pneumonia, Pathogen resistance, Nasopharyngitis, Sputum discoloured, Decreased immune responsiveness, Asthma, |
||||
DUPILUMAB, DUPILUMAB, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, MONTELUKAST SODIUM, MONTELUKAST SODIUM, MONTELUKAST SODIUM, ROSUVASTATIN, IRBESARTAN, AMLODIPINE, PANTOPRAZOLE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ALBUTEROL SULFATE, TIOTROPIUM BROMIDE, |
||||
| 1246 | 26737796 |
US |
70 | 2 |
Asthma, Dyspnoea, Oxygen saturation decreased, |
||||
DUPILUMAB, |
||||
| 1247 | 26737825 |
US |
63 | 1 |
Nasal polyps, Asthma, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1248 | 26737909 |
US |
45 | |
Eye disorder, Eyelid margin crusting, Skin burning sensation, Skin irritation, Asthma, Cough, Throat tightness, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1249 | 26737920 |
US |
76 | 2 |
Asthma, |
||||
DUPILUMAB, |
||||
| 1250 | 26738116 |
US |
68 | 2 |
Hypothyroidism, Narcolepsy, Psoriasis, Arthralgia, Therapy interrupted, Asthma, Depression, |
||||
APREMILAST, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE OINTMENT USP, 0.05%, SOLRIAMFETOL, ALBUTEROL SULFATE, LISDEXAMFETAMINE, GABAPENTIN, ESZOPICLONE, DULOXETINE HYDROCHLORIDE, DULOXETINE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, CARBIDOPA AND LEVODOPA, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, LISDEXAMFETAMINE DIMESYLATE, FLUTICASONE PROPIONATE AND SALMETEROL, ZALEPLON, ROFLUMILAST, |
||||
| 1251 | 26738550 |
CA |
46 | |
Adrenal insufficiency, Nasal polyps, Sensitivity to weather change, Urticaria, Asthma, Off label use, |
||||
OMALIZUMAB, OMALIZUMAB, GLYCOPYRROLATE, MONTELUKAST, ALBUTEROL SULFATE, ALBUTEROL, TEZEPELUMAB-EKKO, PREDNISONE, |
||||
| 1252 | 26738758 |
US |
64 | 2 |
Asthma, Product dose omission issue, Device leakage, Device malfunction, |
||||
BENRALIZUMAB, DUPILUMAB, |
||||
| 1253 | 26738845 |
CA |
74 | 2 |
Diabetes mellitus, Arthralgia, Asthma, Asthmatic crisis, Blood pressure systolic increased, Cough, Hypersensitivity, Illness, Injection site erythema, Injection site scab, Peripheral swelling, Productive cough, Respiratory rate increased, Sensitivity to weather change, Stress, Weight decreased, Wheezing, Wrong technique in product usage process, Drug ineffective, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, DICLOFENAC SODIUM, DICLOFENAC SODIUM, DICLOFENAC SODIUM, VALSARTAN, VALSARTAN ORAL, VALSARTAN, VALSARTAN ORAL, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, PANTOPRAZOLE SODIUM, PANTOPRAZOLE, PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE, PANTOPRAZOLE SODIUM INJECTION, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ROSUVASTATIN CALCIUM, FLUTICASONE FUROATE, MONTELUKAST SODIUM, TIOTROPIUM BROMIDE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 1254 | 26738866 |
CA |
2 | |
Asthma, Drug hypersensitivity, Dyspnoea, Oedema, Pneumonia, Vomiting, Wheezing, |
||||
ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, AMLODIPINE, CALCIUM CARBONATE, ANTACID, CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFOLXACIN, CIPROFLOXACIN TABLETS, CLONAZEPAM, ERGOCALCIFEROL, FOLIC ACID, MONTELUKAST, MOXIFLOXACIN, MOXIFLOXACIN HYDROCHLORIDE, PREDNISONE, THEOPHYLLINE, THEOPHYLLINE ANHYDROUS, OMALIZUMAB, RITUXIMAB, OCRELIZUMAB, ROSUVASTATIN CALCIUM, RISEDRONATE SODIUM, ROPIVACAINE HYDROCHLORIDE, |
||||
| 1255 | 26739014 |
US |
49 | 2 |
Asthma, |
||||
DUPILUMAB, |
||||
| 1256 | 26739050 |
US |
2 | |
Asthma, |
||||
DUPILUMAB, |
||||
| 1257 | 26739081 |
US |
6 | 1 |
Autism spectrum disorder, Respiratory syncytial virus infection, Asthma, Eosinophilic oesophagitis, Insomnia, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 1258 | 26739132 |
US |
50 | 2 |
Asthma, |
||||
DUPILUMAB, |
||||
| 1259 | 26739136 |
US |
2 | |
Asthma, |
||||
DUPILUMAB, |
||||
| 1260 | 26739204 |
US |
2 | |
Asthma, |
||||
DUPILUMAB, |
||||
| 1261 | 26739216 |
US |
63 | 2 |
Nasopharyngitis, Asthma, Wheezing, Sleep disorder due to a general medical condition, |
||||
DUPILUMAB, |
||||
| 1262 | 26739517 |
US |
82 | 2 |
Infection, Asthma, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1263 | 26739531 |
US |
73 | 2 |
Asthma, Cerebral disorder, |
||||
SARILUMAB, |
||||
| 1264 | 26739551 |
US |
70 | 2 |
Dyspnoea, Asthma, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1265 | 26740187 |
US |
2 | |
Asthma, |
||||
DUPILUMAB, |
||||
| 1266 | 26740257 |
EU |
||
Off label use, Anaphylactic reaction, Angioedema, Conjunctivitis, Urticaria, Asthma, Rash, |
||||
IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, |
||||
| 1267 | 26740502 |
US |
37 | 1 |
Asthma, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1268 | 26741099 |
US |
2 | |
Deafness neurosensory, Endocrine ophthalmopathy, Asthma, Gastrointestinal disorder, Large intestine polyp, Osteoporosis, |
||||
TEPROTUMUMAB, PREDNISONE, PREDNISONE, PREDNISONE, DENOSUMAB, THYROID, PORCINE, MOMETASONE FUROATE, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, FLUTICASONE PROPIONATE AND SALMETEROL, METHYLPHENIDATE, METHYLPHENIDATE HYDROCHLORIDE, MIRABEGRON, ALBUTEROL SULFATE, THEOPHYLLINE, THEOPHYLLINE ANHYDROUS, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, |
||||
| 1269 | 26741154 |
US |
70 | 1 |
Asthma, Rash, |
||||
DUPILUMAB, |
||||
| 1270 | 26741220 |
US |
2 | |
Viral infection, Asthma, |
||||
DUPILUMAB, |
||||
| 1271 | 26741294 |
US |
2 | |
Cough, Secretion discharge, Chest discomfort, Asthma, Hypersensitivity, Limb discomfort, Pain in extremity, Off label use, |
||||
BELIMUMAB, FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, FLUTICASONE FUROATE AND VILANTEROL TRIFENATATE, IPRATROPIUM BROMIDE, |
||||
| 1272 | 26733801 |
US |
9 | 1 |
Asthma, Therapeutic response decreased, Eczema, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1273 | 26733804 |
US |
2 | |
Asthma, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 1274 | 26733834 |
US |
52 | 2 |
Asthma, |
||||
DUPILUMAB, ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 1275 | 26733966 |
US |
37 | 2 |
Asthma, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 1276 | 26733975 |
US |
2 | |
Dry eye, Asthma, |
||||
DUPILUMAB, IBUPROFEN, PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, ALBUTEROL SULFATE AND BUDESONIDE, |
||||
| 1277 | 26734001 |
US |
59 | 1 |
Asthma, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1278 | 26734021 |
US |
67 | 1 |
Asthma, Therapeutic response shortened, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1279 | 26734032 |
US |
32 | 2 |
Asthma, Rash, Eye irritation, |
||||
DUPILUMAB, DUPILUMAB, MONTELUKAST SODIUM, IRON, FLUTICASONE PROPIONATE, ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 1280 | 26734080 |
US |
60 | 2 |
Asthma, Product dose omission in error, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 1281 | 26734137 |
US |
32 | 2 |
Asthma, |
||||
DUPILUMAB, |
||||
| 1282 | 26734282 |
US |
2 | |
Asthma, Cough, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 1283 | 26734381 |
US |
38 | 1 |
Asthma, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 1284 | 26734386 |
US |
65 | 2 |
Chronic obstructive pulmonary disease, Asthma, Dyspnoea, Injection site pain, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1285 | 26734397 |
US |
39 | 2 |
Asthma, |
||||
DUPILUMAB, CETIRIZINE HCL, CETIRIZINE, LEVALBUTEROL TARTRATE, |
||||
| 1286 | 26734416 |
US |
58 | 2 |
Muscle discomfort, Taste disorder, Stomatitis, Asthma, Cough, Nasal congestion, |
||||
DUPILUMAB, DUPILUMAB, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, ALBUTEROL SULFATE, ALBUTEROL, METHOTREXATE, METHOTREXATE SODIUM, |
||||
| 1287 | 26734489 |
US |
35 | 2 |
Asthma, |
||||
DUPILUMAB, |
||||
| 1288 | 26734520 |
US |
46 | 2 |
Asthma, |
||||
DUPILUMAB, |
||||
| 1289 | 26734568 |
US |
60 | 2 |
Asthma, Intentional product misuse, |
||||
DUPILUMAB, |
||||
| 1290 | 26734576 |
US |
18 | 1 |
Asthma, Influenza, |
||||
DUPILUMAB, |
||||
| 1291 | 26734609 |
US |
62 | 1 |
Eye irritation, Asthma, |
||||
DUPILUMAB, HYDROCHLOROTHIAZIDE, LOSARTAN POTASSIUM, LOSARTAN, MONTELUKAST SODIUM, MONTELUKAST, |
||||
| 1292 | 26734647 |
CA |
56 | 1 |
Pneumonitis, Influenza, Asthma, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1293 | 26734689 |
US |
12 | 2 |
Eosinophilic oesophagitis, Dysphagia, Hypersensitivity, Asthma, |
||||
DUPILUMAB, IRON, |
||||
| 1294 | 26734726 |
US |
2 | |
Asthma, Dyspnoea, |
||||
DUPILUMAB, ALBUTEROL SULFATE, ALPRAZOLAM, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, PHENTERMINE HYDROCHLORIDE, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, |
||||
| 1295 | 26734729 |
US |
76 | 2 |
Illness, Depressed mood, Asthma, Dyspnoea, |
||||
DUPILUMAB, |
||||
| 1296 | 26734775 |
US |
2 | |
Asthma, Product dose omission issue, |
||||
DUPILUMAB, ALBUTEROL SULFATE, VARENICLINE TARTRATE, FAMOTIDINE, LISINOPRIL, MONTELUKAST, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, TOPIRAMATE, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, |
||||
| 1297 | 26734783 |
US |
55 | 2 |
Rash erythematous, Pain, Asthma, |
||||
DUPILUMAB, |
||||
| 1298 | 26734816 |
US |
2 | |
Illness, Asthma, |
||||
DUPILUMAB, |
||||
| 1299 | 26734845 |
US |
74 | 2 |
Asthma, Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 1300 | 26734858 |
US |
1 | |
Asthma, Product dose omission issue, |
||||
DUPILUMAB, LISINOPRIL, MONTELUKAST SODIUM, MONTELUKAST, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30